Suchergebnisse - "Pietrantuono, Giuseppe"

PubPharm (90)

1

IELSG38 : phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

enthalten in: Haematologica | 2024

von Stathis, A. | Pirosa, M. | Orsucci, L. | +44

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

3

What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study

enthalten in: Cancers | 2024

von D'Arena, G. | Vitale, C. | Pietrantuono, G. | +15

4

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129) : final analysis of a non-randomised, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2023

von van de Donk, N. | Minnema, M. | van der Holt, B. | +25

5

Comparative analyses of DNA extraction methods for whole blood quantification of HCMV DNAemia in patients with hematological diseases : false negative cases in manual method

enthalten in: Heliyon | 2023

von Bianchino, G. | Grieco, V. | Pietrantuono, G. | +4

6

Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia

enthalten in: Cancer medicine | 2023

von Valvano, L. | Nozza, F. | D'Arena, G. | +9

7

Preliminary analysis of double‐negative T, double‐positive T, and natural killer T‐like cells in B‐cell chronic lymphocytic leukemia

enthalten in: Cancer Medicine | 2023

von Valvano, L. | Nozza, F. | D'Arena, G. | +9

8

Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia : Where do we stand?

enthalten in: Hematological oncology | 2022

von D'Arena, G. | Sgambato, A. | Volpe, S. | +11

9

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

10

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Bertamini, L. | Oliva, S. | Rota-Scalabrini, D. | +26

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3099-3102. - PMID 35759726

1
2
3
4
5
6
7
8
9
Nächster »
[9]